Department of Dairy Microbiology, Molecular Biology Unit, National Dairy Research Institute, Karnal, 132001, Haryana, India.
Genes Nutr. 2013 Nov;8(6):637-48. doi: 10.1007/s12263-013-0347-5. Epub 2013 Jun 2.
The anti-inflammatory potential of eight indigenous probiotic Lactobacillus isolates was evaluated in vitro in terms of modulating the expression of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in human acute monocytic leukemia (THP-1) cells under inflammatory conditions. Amongst these, Lactobacillus plantarum Lp91 was the most potent anti-inflammatory strain as it evoked a significant (P < 0.001) down-regulation of TNF-α by -1.45-fold relative to the control in THP-1 cells. However, in terms of IL-6 expression, all the strains could up-regulate its expression considerably at different levels. Hence, based on in vitro expression of TNF-α, Lp91 was selected for in vivo study in lipopolysaccharide (LPS)-induced mouse model to look at the expression of TNF-α, IL-6, monocyte chemotactic protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule (ICAM-1) and E-selectin in mouse aorta. In LPS challenged (2 h) mice group fed with Lp91 for 10 days, TNF-α, IL-6, MCP-1, VCAM-1, ICAM-1 and E-selectin expressions were significantly down-regulated by 3.10-, 10.02-, 4.22-, -3.14-, 2.28- and 5.71-fold relative to control conditions. In conclusion, Lp91 could serve as a candidate probiotic strain to explore it as a possible biotherapeutic anti-inflammatory agent against inflammatory diseases including cardiovascular disease.
评估了 8 种本土益生菌 Lactobacillus 分离株在体外对人急性单核细胞白血病 (THP-1) 细胞中肿瘤坏死因子-α (TNF-α) 和白细胞介素-6 (IL-6) 表达的调节作用。在这些分离株中,植物乳杆菌 Lp91 是最有效的抗炎菌株,因为它在 THP-1 细胞中使 TNF-α的表达下调了 -1.45 倍,与对照相比具有显著差异 (P < 0.001)。然而,就 IL-6 的表达而言,所有菌株都可以在不同水平上显著上调其表达。因此,根据 TNF-α 的体外表达,选择 Lp91 进行脂多糖 (LPS) 诱导的小鼠模型的体内研究,以观察 TNF-α、IL-6、单核细胞趋化蛋白-1 (MCP-1)、血管细胞黏附分子-1 (VCAM-1)、细胞间黏附分子 (ICAM-1) 和 E-选择素在小鼠主动脉中的表达。在 LPS 挑战 (2 小时) 的小鼠组中,用 Lp91 喂养 10 天后,TNF-α、IL-6、MCP-1、VCAM-1、ICAM-1 和 E-选择素的表达分别下调了 3.10 倍、10.02 倍、4.22 倍、-3.14 倍、2.28 倍和 5.71 倍,与对照条件相比。综上所述,Lp91 可以作为候选益生菌菌株,探索其作为一种可能的生物治疗抗炎剂,用于治疗包括心血管疾病在内的炎症性疾病。